Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $9.00.

A number of brokerages recently issued reports on PYXS. Stephens started coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.57 on Friday. The company has a fifty day moving average of $1.65 and a two-hundred day moving average of $2.94. The company has a market capitalization of $93.36 million, a PE ratio of -1.52 and a beta of 1.06. Pyxis Oncology has a 1 year low of $1.39 and a 1 year high of $6.85.

Insider Activity at Pyxis Oncology

In other news, CFO Pamela Ann Connealy acquired 88,850 shares of Pyxis Oncology stock in a transaction that occurred on Tuesday, November 26th. The stock was purchased at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now directly owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of PYXS. Intech Investment Management LLC acquired a new stake in shares of Pyxis Oncology in the third quarter valued at about $55,000. SG Americas Securities LLC purchased a new position in Pyxis Oncology in the third quarter valued at about $58,000. The Manufacturers Life Insurance Company purchased a new position in Pyxis Oncology in the second quarter valued at about $65,000. MetLife Investment Management LLC lifted its position in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth approximately $107,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.